Search Results - "LOBO, Evelyn D"

Antibody pharmacokinetics and pharmacodynamics by Lobo, Evelyn D, Hansen, Ryan J, Balthasar, Joseph P

“…The U.S. Food and Drug administration (FDA) has approved several polyclonal antibody preparations and at least 18 monoclonal antibody preparations (antibodies,…”
Get more information

Pharmacokinetic-pharmacodynamic modeling of methotrexate-induced toxicity in mice by Lobo, Evelyn D, Balthasar, Joseph P

“…The prediction of chemotherapeutic efficacy is complicated by "protocol dependencies" in dose-effect and dose-toxicity relationships. It has been proposed that…”
Get more information

Pharmacokinetics of Orally Administered Duloxetine in Children and Adolescents with Major Depressive Disorder by Lobo, Evelyn D., Quinlan, Tonya, Prakash, Apurva

“…Background Duloxetine, a selective serotonin (5-hydroxytryptamine) and norepinephrine reuptake inhibitor, has been approved since 2004 for the treatment of…”
Get full text

Results from clinical trials of a selective ionotropic glutamate receptor 5 (iGluR5) antagonist, LY5454694 tosylate, in 2 chronic pain conditions by Chappell, Amy S., Iyengar, Smriti, Lobo, Evelyn D., Prucka, William R.

“…No proof-of-principle for iGluR5 antagonism as a chronic pain treatment was demonstrated in 2 studies of osteoarthritis of the knee and diabetic peripheral…”
Get full text

In Vitro and In Vivo Evaluations of Cytochrome P450 1A2 Interactions with Duloxetine by Lobo, Evelyn D., Bergstrom, Richard F., Reddy, Shobha, Quinlan, Tonya, Chappell, Jill, Hong, Quan, Ring, Barbara, Knadler, Mary Pat

“…Objective: To determine whether duloxetine is a substrate, inhibitor or inducer of cytochrome P450 (CYP) 1A2 enzyme, using in vitro and in vivo studies in…”
Get full text

Safety, tolerability, pharmacokinetics, and effects on human experimental pain of the selective ionotropic glutamate receptor 5 (iGluR5) antagonist LY545694 in healthy volunteers by Petersen, Karin L., Iyengar, Smriti, Chappell, Amy S., Lobo, Evelyn D., Reda, Haatem, Prucka, William R., Verfaille, Steven J.

“…In a 2-part study in healthy volunteers, we first established a maximally tolerated multiple dose of LY545694 of 25mg twice daily and subsequently demonstrated…”
Get full text

Optimization of LY545694 Tosylate Controlled Release Tablets Through Pharmacoscintigraphy by Lobo, Evelyn D., Argentine, Mark D., Sperry, David C., Connor, Alyson, McDermott, John, Stevens, Lloyd, Almaya, Ahmad

“…ABSTRACT Purpose To optimize a controlled release (CR) matrix formulation with two goals: (1) effectively deliver a prodrug to a preferred absorption region of…”
Get full text

Population Pharmacokinetics of Orally Administered Duloxetine in Patients: Implications for Dosing Recommendation by Lobo, Evelyn D., Quinlan, Tonya, O’Brien, Lisa, Knadler, Mary Pat, Heathman, Michael

“…Objectives: The objectives of this analysis were to characterize the pharmacokinetics of duloxetine at steady state in patients, estimate the variability,…”
Get full text

Effects of Varying Degrees of Renal Impairment on the Pharmacokinetics of Duloxetine: Analysis of a Single-Dose Phase I Study and Pooled Steady-State Data from Phase II/III Trials by Lobo, Evelyn D., Heathman, Michael, Kuan, Han-Yi, Reddy, Shobha, O’Brien, Lisa, Gonzales, Celedon, Skinner, Michael, Knadler, Mary Pat

“…Background Duloxetine is indicated for patients with a variety of conditions, and some of these patients may have mild to moderate degrees of renal impairment…”
Get full text

Effects of duloxetine on norepinephrine and serotonin transporter activity in healthy subjects by Chappell, Jill C, Eisenhofer, Graeme, Owens, Michael J, Haber, Harry, Lachno, D Richard, Dean, Robert A, Knadler, Mary Pat, Nemeroff, Charles B, Mitchell, Malcolm I, Detke, Michael J, Iyengar, Smriti, Pangallo, Beth, Lobo, Evelyn D

“…Duloxetine selectively inhibits the serotonin (5-HT) and norepinephrine (NE) transporters (5-HTT and NET, respectively), as demonstrated in vitro and in…”
Get full text

Pharmacokinetics of Duloxetine in Breast Milk and Plasma of Healthy Postpartum Women by Lobo, Evelyn D., Loghin, Corina, Knadler, Mary Pat, Quinlan, Tonya, Zhang, Lu, Chappell, Jill, Lucas, Richard, Bergstrom, Richard F.

“…Objective: The purpose of this study was to characterize duloxetine pharmacokinetics in the breast milk and plasma of lactating women and to estimate the…”
Get full text

Evaluation of methods for achieving stable INR in healthy subjects during a multiple-dose warfarin study by Chappell, Jill C., Dickinson, Gemma, Mitchell, Malcolm I., Haber, Harry, Jin, Yan, Lobo, Evelyn D.

“…Purpose No consistent method is available for finding stable warfarin maintenance doses and fast stabilization of international normalized ratio (INR) values…”
Get full text

Oral Olanzapine Disposition in Adolescents with Schizophrenia or Bipolar I Disorder: A Population Pharmacokinetic Model by Lobo, Evelyn D., Robertson-Plouch, Carol, Quinlan, Tonya, Hong, Quan, Bergstrom, Richard F.

“…Background Olanzapine is an atypical antipsychotic approved for the treatment of adults and adolescents (aged 13–17 years) with schizophrenia or bipolar I…”
Get full text

Pharmacodynamic modeling of chemotherapeutic effects: application of a transit compartment model to characterize methotrexate effects in vitro by Lobo, Evelyn D, Balthasar, Joseph P

“…The time course of chemotherapeutic effect is often delayed relative to the time course of chemotherapeutic exposure. In many cases, this delay is difficult to…”
Get full text

Pharmacokinetics and tolerability of duloxetine following oral administration to healthy chinese subjects by TIANMEI, Si, PAT KNADLER, Mary, LIM, Ming T, KWEE POO YEO, LEYAN TENG, SHU LIANG, PAN, Alan X, LOBO, Evelyn D

“…The objectives of the study were to characterise the pharmacokinetics and assess the tolerability of duloxetine in healthy Chinese subjects after single and…”
Get full text

Application of anti-methotrexate Fab fragments for the optimization of intraperitoneal methotrexate therapy in a murine model of peritoneal cancer by Lobo, Evelyn D, Balthasar, Joseph P

“…Anti-drug antibodies may be used to impart regio-specific alterations in drug disposition, potentially enhancing the therapeutic selectivity of intracavitary…”
Get more information

Application of pharmacokinetic-pharmacodynamic modeling to predict the kinetic and dynamic effects of anti-methotrexate antibodies in mice by Lobo, Evelyn D, Soda, David M, Balthasar, Joseph P

“…We have shown that intravenous (i.v.) administration of anti-methotrexate (MTX) antibodies (AMAb) reduces the systemic exposure of intraperitoneal (i.p.) MTX…”
Get more information

Oral Olanzapine Disposition in Adolescents with Schizophrenia or Bipolar I Disorder by Lobo, Evelyn D, Robertson-Plouch, Carol, Quinlan, Tonya, Hong, Quan, Bergstrom, Richard F

“…Background Olanzapine is an atypical antipsychotic approved for the treatment of adults and adolescents (aged 13-17 years) with schizophrenia or bipolar I…”
Get full text

Highly sensitive high-performance liquid chromatographic assay for methotrexate in the presence and absence of anti-methotrexate antibody fragments in rat and mouse plasma by Lobo, Evelyn D, Balthasar, Joseph P

“…Recently, Balthasar and Fung have proposed that anti-methotrexate antibody fragments may be employed to enhance the selectivity of intraperitoneal methotrexate…”
Get full text

Oral olanzapine disposition in adolescents with schizophrenia or bipolar I disorder: a population pharmacokinetic model by Lobo, Evelyn D, Robertson-Plouch, Carol, Quinlan, Tonya, Hong, Quan, Bergstrom, Richard F

“…Olanzapine is an atypical antipsychotic approved for the treatment of adults and adolescents (aged 13 -17 years) with schizophrenia or bipolar I disorder…”
Get more information